Arcadia Biosciences, Inc. Enters into Securities Purchase Agreement for Private Placement

On June 11, 2026, Arcadia Biosciences, Inc. entered into a securities purchase agreement with an institutional accredited investor for a private placement of pre-funded warrants and investment options. The transaction is expected to raise approximately $4 million before expenses. The pre-funded warrants are exercisable for one share of common stock at an exercise price of $0.0001 per share, and the investment options are exercisable at $0.91 per share. The company has agreed to hold a stockholder meeting to approve the issuance of shares related to the Series A-1 investment options. The agreement includes customary representations, warranties, and covenants, as well as restrictions on the company's future stock issuances. A registration rights agreement was also entered into, requiring the company to file a resale registration statement for the offered securities. The company engaged H.C. Wainwright & Co. as its placement agent and paid fees and issued placement agent options in connection with the transaction. The securities were offered in reliance on exemptions from registration under the Securities Act of 1933.